Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Current Leases (2019 - 2025)

Northwest Biotherapeutics (NWBO) has 7 years of Current Leases data on record, last reported at $399000.0 in Q3 2025.

  • For Q3 2025, Current Leases rose 55.86% year-over-year to $399000.0; the TTM value through Sep 2025 reached $399000.0, up 55.86%, while the annual FY2024 figure was $326000.0, 3.82% up from the prior year.
  • Current Leases reached $399000.0 in Q3 2025 per NWBO's latest filing, down from $448000.0 in the prior quarter.
  • Across five years, Current Leases topped out at $448000.0 in Q2 2025 and bottomed at $170000.0 in Q1 2021.
  • Average Current Leases over 5 years is $318894.7, with a median of $326000.0 recorded in 2024.
  • Peak YoY movement for Current Leases: plummeted 55.73% in 2021, then soared 156.0% in 2025.
  • A 5-year view of Current Leases shows it stood at $317000.0 in 2021, then grew by 11.67% to $354000.0 in 2022, then dropped by 11.3% to $314000.0 in 2023, then rose by 3.82% to $326000.0 in 2024, then increased by 22.39% to $399000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Current Leases were $399000.0 in Q3 2025, $448000.0 in Q2 2025, and $390000.0 in Q1 2025.